Summary:
A Phase 3 Double-Blinded Placebo-controlled efficacy and safety study of Firibastat (QGC001) Administered Orally, Twice Daily over 12 weeks in difficult to treat/resistant hypertensive subjects
Qualified Participants Must:
• Age 18 and over
•
Diagnosed with hypertension (high blood pressure) for at least 6 months
•
Take at least 2 blood pressure medications
•
Have a top number blood pressure reading between 140-180